| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R44TR002350 | Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | 000 | 3 | NIH | 5/15/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $41,550 ) |
| | 2022 | 2022 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R43DK129187 | Small molecule enhancers of detrusor contraction discovered using a functional cell contractility screen as therapeutic candidates for underactive bladder | 000 | 1 | NIH | 4/7/2022 | $41,550 |
| | 2022 | 2020 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R44TR002350 | Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | 000 | 3 | NIH | 12/24/2021 | $0 |
| | 2022 | 2020 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R44TR002350 | Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | 000 | 3 | NIH | 12/24/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $702,511 ) |
| | 2021 | 2021 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R43DK129187 | Small molecule enhancers of detrusor contraction discovered using a functional cell contractility screen as therapeutic candidates for underactive bladder | 000 | 1 | NIH | 6/14/2021 | $352,511 |
| | 2021 | 2021 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R41GM146269 | Smart, integrated well-plates for ultra-high-throughput screening of excitation-contraction coupling in tissues | 000 | 1 | NIH | 9/14/2021 | $350,000 |
|
| Issue Date FY: 2020 ( Subtotal = $876,721 ) |
| | 2020 | 2020 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R44TR002350 | Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | 001 | 3 | NIH | 6/18/2020 | $137,283 |
| | 2020 | 2020 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R44TR002350 | Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | 000 | 2 | NIH | 5/14/2020 | $66,248 |
| | 2020 | 2020 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R44TR002350 | Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | 001 | 3 | NIH | 6/18/2020 | $673,190 |
| | 2020 | 2018 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R43AT009962 | High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies | 000 | 1 | NIH | 12/1/2019 | $0 |
| | 2020 | 2018 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R43HD097002 | High-throughput screening of uterine smooth muscle contractility towards therapies to prevent pre-term birth | 000 | 1 | NIH | 6/4/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $848,353 ) |
| | 2019 | 2019 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R44TR002350 | Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | 000 | 2 | NIH | 8/6/2019 | $826,810 |
| | 2019 | 2019 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R44TR002350 | Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension | 001 | 2 | NIH | 9/4/2019 | $0 |
| | 2019 | 2019 | FORCYTE BIOTECHNOLOGIES, INC. | 11957 DARLINGTON AVE 202 | LOS ANGELES | CA | 90049-5626 | LOS ANGELES | USA | R43AT009962 | High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies | 000 | 1 | NIH | 2/6/2019 | $21,543 |
| | 2019 | 2018 | FORCYTE BIOTECHNOLOGIES, INC. | 1100 GLENDON AVE FL 17 | LOS ANGELES | CA | 90024-3588 | LOS ANGELES | USA | R43TR002350 | Multiplexed single-cell contractility assay to develop therapeutics for asthma and hypertension | 000 | 1 | NIH | 5/1/2019 | $0 |
| | 2019 | 2018 | FORCYTE BIOTECHNOLOGIES, INC. | 11957 DARLINGTON AVE 202 | LOS ANGELES | CA | 90049-5626 | LOS ANGELES | USA | R43HD097002 | High-throughput screening of uterine smooth muscle contractility towards therapies to prevent pre-term birth | 000 | 1 | NIH | 3/13/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $716,472 ) |
| | 2018 | 2018 | FORCYTE BIOTECHNOLOGIES, INC. | 11957 DARLINGTON AVE 202 | LOS ANGELES | CA | 90049-5626 | LOS ANGELES | USA | R43AT009962 | High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies | 000 | 1 | NIH | 4/3/2018 | $224,905 |
| | 2018 | 2018 | FORCYTE BIOTECHNOLOGIES, INC. | 11957 DARLINGTON AVE 202 | LOS ANGELES | CA | 90049-5626 | LOS ANGELES | USA | R43HD097002 | High-throughput screening of uterine smooth muscle contractility towards therapies to prevent pre-term birth | 000 | 1 | NIH | 7/23/2018 | $224,997 |
| | 2018 | 2018 | FORCYTE BIOTECHNOLOGIES, INC. | 11957 DARLINGTON AVE 202 | LOS ANGELES | CA | 90049-5626 | LOS ANGELES | USA | R43AT009962 | High-throughput screening of vasoprotectors in the brain using single-cell force mapping towards anti-migraine therapies | 001 | 1 | NIH | 9/10/2018 | $41,583 |
| | 2018 | 2018 | FORCYTE BIOTECHNOLOGIES, INC. | 11957 DARLINGTON AVE 202 | LOS ANGELES | CA | 90049-5626 | LOS ANGELES | USA | R43TR002350 | Multiplexed single-cell contractility assay to develop therapeutics for asthma and hypertension | 000 | 1 | NIH | 1/1/2018 | $224,987 |
|
|
